We present a novel protein crystallization strategy, applied to the crystallization of human T cell leukemia virus type I (HTLV-I) transmembrane protein gp21 lacking the fusion peptide and the transmembrane domain, as a chimera with the Escherichia coli maltose binding protein (MBP). Crystals could not be obtained with a MBP/gp21 fusion protein in which fusion partners were separated by a flexible linker, but were obtained after connecting the MBP C-terminal a-helix to the predicted N-terminal a-helical sequence of gp21 via three alanine residues. The gp21 sequences conferred a trimeric structure to the soluble fusion proteins as assessed by sedimentation equilibrium and X-ray diffraction, consistent with the trimeric structures of other retroviral transmembrane proteins. The envelope protein precursor, gp62, is likewise trimeric when expressed in mammalian cells. Our results suggest that MBP may have a general application for the crystallization of proteins containing N-terminal a-helical sequences.Keywords: E. coli protein expression; maltose-binding protein/HTLV-1 gp2 1 chimera; protein crystallization; trimerization; X-ray diffraction Crystallization and phase determination remain the two ratelimiting steps in determining protein crystal structures. The strategy of using fusion proteins comprising a "crystallization tag" of known three-dimensional structure and the protein of interest offers an approach to overcoming these problems. The crystallization conditions and crystal contacts found important in crystallization of the tag may be used to guide the crystallization of the fusion protein. Knowledge of the three-dimensional structure of the crystallization tag should then allow determination of the starting phases by the method of molecular replacement. Moreover, knowledge of the heavy atom-binding sites in the crystallization tag can be used to determine the starting phases by the methods of multiple isomorphous replacement and multi-wavelength anomalous dispersion. The strategy offers similar advantages as co-crystallization with antibody fragments (Air et al., 1987;Prongay et al., 1990;Jacobo-Molina et al., 1991;Ostermeier et al., 1995) while being